BPC-157

01 · What it is

BPC-157 is a synthetic chain of fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of roughly 1,419 Da, described in the originating literature as a partial sequence of a larger protein isolated from human gastric juice ^12,26. It does not occur naturally in this isolated form. The parent protein has never been characterised to the standard the peptide’s description implies, and no endogenous physiological role has been established for either molecule.

It was characterised from the early 1990s onward by a group at the University of Zagreb, and the shape of the literature since then is the most important thing to understand about it: dozens of animal studies spanning tendon, ligament, skeletal and cardiac muscle, gut, liver, brain, eye and vasculature; findings that are strikingly consistent and almost uniformly positive; and, in the entire peer-reviewed record, twenty-nine human subjects ^20,25.

Those twenty-nine come from two uncontrolled studies by the same clinician. Seventeen patients received intra-articular injection for knee pain of mixed cause and were assessed by retrospective chart review and a telephone survey using no validated instrument; sixteen were reached ²⁰. Twelve women with interstitial cystitis received a single 10 mg intravesical injection during cystoscopy and were assessed on a five-point Global Response Assessment questionnaire ²⁵. Neither study had a control group, a blinded assessor, or an objective endpoint. PubMed indexes no randomised controlled trial of BPC-157 for any indication.

The property most often invoked in support of oral administration — that BPC-157 resists degradation in human gastric juice — appears in review articles from the originating group ^12,26. No primary indexed report of that experiment could be located during preparation of this guide. Most peptides are hydrolysed within minutes of reaching the stomach, so if the finding holds it is genuinely unusual and changes how the whole animal literature should be read. As it stands it has not been published in full and has not been independently reproduced.

As of September 2026 BPC-157 holds no marketing authorisation from any regulator.

02 · Evidence at a glance

Evidence grade

Preclinical

Primary animal studies

Dozens, across at least eight organ systems

Human subjects, peer-reviewed record

29

Human studies

2, both uncontrolled, both from one clinic, both with subjective endpoints

Randomised controlled trials

None indexed, for any indication

Human pharmacokinetic data

None indexed, for any route

Molecular target

Not identified

Independent replication

Partial — gastric ulcer, tendon cell behaviour and limb ischaemia-reperfusion reproduced outside the originating group

Published mechanistic disagreement

Yes — a formal Comment and Reply exchange in 2025 ^29,30

Toxicology in the indexed literature

No repeat-dose, genotoxicity, reproductive or carcinogenicity study identified

Approval status

None, any jurisdiction

WADA status

Falls within S0 (non-approved substances), prohibited at all times

03 · Mechanism of action

No identified target

No molecular receptor for BPC-157 has been identified. This is not a gap at the edge of the mechanism, it is the middle of it. Every pathway below was mapped by administering the peptide, measuring what changed downstream, and reasoning backwards — an approach that establishes association rather than a binding target, and that cannot separate a direct effect from a third-order consequence of one. Reviews published between 2019 and 2026 consistently describe the mechanism as incompletely defined for this reason ^17,27,28,32. Without a target there is no receptor occupancy, no selectivity profile, and no principled basis for predicting off-target activity. Read every claim that follows with that qualification attached.

Angiogenesis through VEGFR2

The best-supported pathway, and the only one described in detail by investigators unconnected to the originating laboratory. Hsieh and colleagues reported that BPC-157 promotes vessel formation in chorioallantoic membrane and endothelial tube-formation assays, and accelerates blood-flow recovery and vessel number in rats with hind-limb ischaemia, with the effect associated with activation and upregulation of vascular endothelial growth factor receptor 2 ¹⁵. VEGFR2 is the principal receptor through which VEGF-A drives endothelial proliferation, migration and survival, so an agent that increases its expression has a plausible route to the angiogenic findings that recur throughout the animal work ¹⁶. What the study does not establish is whether BPC-157 binds anything upstream of VEGFR2, or whether the receptor change is cause or consequence.

The nitric oxide system, and a documented disagreement about it

The originating group’s central mechanistic claim is that BPC-157 acts on the nitric oxide system, counteracting both nitric oxide synthase blockade by L-NAME and the effects of excess nitric oxide, which they frame as maintenance of homeostasis rather than a push in either direction ^12,13. Bidirectional counteraction is an unusual property to claim and a difficult one to falsify, since both a rise and a fall in the same signal can be read as confirmation.

That framing is now formally contested in the literature. In September 2025, Pharmaceuticals published a Comment from the Zagreb group disputing the mechanistic account given in a literature-and-patent review, arguing that BPC-157 exhibits a distinctive bidirectional effect on nitric oxide level always coupled to counteraction of free radical formation ²⁹, alongside a Reply from the review’s authors ³⁰. Readers evaluating this compound should read both. A published exchange of this kind is more informative than either paper alone, and it is unusual for a compound of this profile to have generated one.

Focal adhesion turnover in tendon fibroblasts

Chang and colleagues at Chang Gung University reported that BPC-157 accelerated outgrowth from rat Achilles tendon explants, increased cell survival under oxidative stress, and increased fibroblast migration in a dose-dependent manner, with increased F-actin formation and increased phosphorylation of focal adhesion kinase and paxillin ¹¹. FAK and paxillin are core components of focal adhesion turnover, the machinery by which a migrating cell forms and releases attachments to its substrate. This is the most mechanistically specific finding in the BPC-157 literature and one of very few generated by a group with no connection to the originators. It is cell culture only, and cell migration in a dish is several steps removed from tendon healing in an animal.

Growth hormone receptor expression

The same investigators later reported, from cDNA microarray analysis, that growth hormone receptor expression increased in tendon fibroblasts exposed to BPC-157 ¹⁴. That would offer a route by which the peptide could sensitise tendon cells to circulating growth hormone, and it is the only proposed link between BPC-157 and endocrine signalling. The functional consequence has not been tested, has not been demonstrated in a living animal, and has not been replicated.

Cytoprotection as an organising frame

Much of the Zagreb literature is written inside a cytoprotection framework, in which a single agent protects epithelium and endothelium across many organs through a shared vascular mechanism ^16,21,22. The frame has explanatory reach — it accounts for why one peptide would appear to help gut, liver, tendon and brain alike — and that reach is also its weakness. A theory that predicts benefit everywhere is difficult to test anywhere.

04 · Key research findings

Tendon. The most developed body of work and the only one with meaningful outside involvement. In cultured rat tendon explants and fibroblasts, BPC-157 increased outgrowth, migration and survival under oxidative stress ¹¹, and increased growth hormone receptor expression ¹⁴. In a 2026 rat Achilles transection-and-repair model, animals receiving 10 µg/kg/day intraperitoneally for four weeks showed higher maximum load to failure than controls and numerically lower histological degeneration scores, but neither reached statistical significance — while a thymosin β4 fragment, tested in the same experiment under identical conditions, did ³⁵. That study is small, at eight animals per arm, and a single dose level is not a dose-response.

Tendon is where the evidence is deepest, and where the only independent head-to-head test placed BPC-157 second.

Ligament and skeletal muscle. Rats with transected medial collateral ligament followed to 90 days showed improved healing across intraperitoneal, oral and topical administration ⁹, and a 2022 review collects the group’s work on skeletal, smooth and cardiac muscle and on the myotendinous junction ²⁴.

Both literatures are essentially single-group, neither has an independent replication, and the muscle work exists largely as review rather than as separately reported primary experiments.

Skin and granulation tissue. The most methodologically careful animal work in the file, produced by a pharmaceutical company rather than a university. Pliva-affiliated investigators reported accelerated closure and increased collagen deposition in excisional wounds in alloxan-hyperglycaemic rats ⁵, and compared the peptide against PDGF-BB for stimulation of granulation tissue, proposing egr-1 as a mediating immediate-early gene ⁶.

An industrial group ran the best-controlled experiments in this literature and then stopped, and the published record does not say why.

Gastrointestinal tract. The original development rationale and the deepest single-organ dataset. An independent group in China reported protection against acute and chronic gastric ulcers in rats by both intramuscular and oral routes ¹; the Zagreb group reported improved healing of ileoileal anastomoses ⁷ and of gastrocutaneous fistulas against active comparators including omeprazole and ranitidine ^8,19; and a separate group reported protection against NSAID-induced cytotoxicity with stabilisation of intestinal permeability ¹⁸.

This is the only organ system in which a positive BPC-157 finding has been reproduced by investigators with no connection to the originators.

Vasculature and ischaemia-reperfusion. The Zagreb group has reported effects on major vessel occlusion syndromes, Pringle-manoeuvre ischaemia-reperfusion injury and Budd-Chiari syndrome in rats ²². In 2026 an independent group in Türkiye reported protection against lower-limb ischaemia-reperfusion injury in rats, with reductions in markers of oxidative stress, inflammation and apoptosis ³⁴.

This is the newest independent replication in the literature and the one most worth watching, because it tests the vascular mechanism that the cytoprotection frame depends on.

Central nervous system and systemic toxicity models. Rats given a hepatotoxic dose of paracetamol showed fewer generalised convulsions and less brain damage with BPC-157 ¹⁰; mice given acute and chronic ethanol showed less gastric and hepatic lesioning ²; rats in a serotonin syndrome model showed altered behavioural outcomes ⁴; and a 2022 review collects reported effects in models of Parkinson-like and Alzheimer-like disturbance, encephalopathy and neurotransmitter signalling ²³.

The breadth here is striking and the depth is not: these are largely single-group reports, several of them surviving only inside review articles, with no independent confirmation of any central effect.

Eye. Corneal epithelial defect healing was dose-dependent in a four-group rat study of 48 animals ³.

A single small study, never followed up in fifteen years.

Humans. Fourteen of sixteen patients contacted after intra-articular BPC-157 for knee pain reported relief, with no imaging, no control group and no validated instrument ²⁰. All twelve women receiving a single intravesical injection for interstitial cystitis scored maximally on the Global Response Assessment, and no adverse events or dropouts were reported ²⁵. Neither study measured anything a blinded observer could have checked.

Twenty-nine people, no controls, subjective endpoints, one clinic — and near-perfect response rates in uncontrolled series of pain and symptom conditions are exactly the pattern that controlled trials most often fail to reproduce.

05 · Evidence overview

06 · Safety profile

Animal data. The animal literature is efficacy-focused, and this review did not identify a published repeat-dose toxicology study, genotoxicity battery, reproductive or developmental toxicity study, or carcinogenicity study of BPC-157 in the indexed literature. Individual efficacy papers report no overt toxicity at the doses used, which are typically in the microgram-per-kilogram range and administered for days to weeks ^5,9,35. Absence of overt toxicity in an experiment designed to measure healing is not a safety finding and should not be read as one: such studies are not powered for harm, do not follow animals beyond the healing window, and rarely include the histopathology or clinical chemistry that toxicology requires.

Human data. Both human studies reported no adverse events. The interstitial cystitis pilot noted no dropouts and no adverse events across twelve subjects following a single procedure ²⁵; the knee pain series was retrospective and collected its safety information by telephone survey months to a year after injection, a method that cannot reliably capture adverse events and was not designed to ²⁰. Twenty-nine people, none monitored systematically, is the entire human safety database.

What is genuinely unknown. No repeated-administration data in humans beyond a single procedure or a short course, in any indication. No reproductive, developmental, or hormonal data in either sex, in any species. No carcinogenicity data in any species. No immunogenicity data in humans, despite parenteral administration of a 15-residue peptide being precisely the exposure most likely to generate an antibody response, and despite characterisation and aggregation being identified as unresolved problems for this molecule ³². No interaction data with any drug class. And one specific gap follows directly from the mechanism: the best-evidenced pathway is upregulation of VEGFR2 ¹⁵, a receptor central to tumour angiogenesis, and no study has examined what systemic administration does in the presence of undiagnosed malignancy.

07 · US regulatory status

Current as of 6 September 2026. BPC-157 is not approved as a drug in the United States or any other jurisdiction, and is not a controlled substance.

In September 2023 FDA placed BPC-157 in category 2 of its interim bulk drug substances policy — substances that may present significant safety risks. As of FDA’s page dated 22 April 2026 that entry has moved to the table of substances nominated but subsequently withdrawn by the nominators ³⁷. On 23 July 2026 FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 for possible inclusion on the 503A Bulks List, for the proposed use of ulcerative colitis ³⁸. Advisory committee recommendations are non-binding; nothing has been added to that list as a result, and inclusion would require formal rulemaking.

Under the World Anti-Doping Code, pharmacological substances not approved by any governmental regulatory health authority for human therapeutic use fall within category S0 and are prohibited at all times, in and out of competition.

08 · Limitations of the evidence

1. Animal-to-human translation is unestablished at every step. Most efficacy work used intraperitoneal administration or drinking water in rodents, over days to weeks, in acute injury models created surgically or chemically. None of those conditions corresponds to a human, and no human pharmacokinetic study exists to bridge the gap. Nothing is known about what concentration of BPC-157 reaches which tissue in a person, by any route.

1. No randomised controlled trial exists. Not a small one, not a negative one — none is indexed for any indication. The two human studies are uncontrolled case series with subjective endpoints from a single clinic ^20,25. Uncontrolled series in pain and symptom conditions routinely report high response rates that controlled trials do not reproduce, because they cannot separate treatment from natural history, regression to the mean, or expectation.

1. Research concentration limits verification. A large majority of the animal literature originates with one group and its collaborators. Independent reproduction exists for gastric ulcer ¹, tendon cell behaviour ¹¹ and limb ischaemia-reperfusion ³⁴, and not for the ligament, muscle, central nervous system, eye or vessel-occlusion findings. A result confirmed only by the people who first reported it is a weaker result.

1. Publication bias is visible in the shape of the record. Findings are positive across tendon, ligament, muscle, gut, liver, brain, eye and vasculature, in multiple species and model types, almost without exception. Mature research fields do not look like this. The near-total absence of null results is itself evidence about what has been submitted and published, not evidence about the compound.

1. The molecular target is unknown. Mechanism has been inferred from downstream changes rather than demonstrated at a binding site ^17,27,32. Without a target, dose-response cannot be modelled, selectivity cannot be assessed, and off-target risk cannot be reasoned about even in principle. A formal disagreement about the mechanistic account is now on the record ^29,30.

1. Characterisation and identity are unresolved. Peptide-related impurities, aggregation and difficulty characterising the active ingredient are documented problems for this molecule ³². That is a scientific reproducibility issue before it is anything else: two laboratories reporting on “BPC-157” may not have administered identical material, and few papers report independent verification of what they used.

1. The oral stability finding rests on unpublished work. The property that would most change how this literature should be interpreted — resistance to hydrolysis in gastric juice — appears in reviews ^12,26 without an indexed primary report behind it. Until that experiment is published in full, every oral-administration inference in the field rests on an unverifiable foundation.

09 · References

1. Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032–1036.

   PMID 15052688 ↗

2. Blagaic AB, Blagaic V, Romic Z, Sikiric P. The influence of gastric pentadecapeptide BPC 157 on acute and chronic ethanol administration in mice. Eur J Pharmacol. 2004;499(3):285–290.

   PMID 15381050 ↗

3. Lazić R, Gabrić N, Dekaris I, Bosnar D, Boban-Blagaić A, Sikirić P. Gastric pentadecapeptide BPC 157 promotes corneal epithelial defects healing in rats. Coll Antropol. 2005;29(1):321–325.

   PMID 16117343 ↗

4. Boban Blagaic A, Blagaic V, Mirt M, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512(2–3):173–179.

   PMID 15840402 ↗

5. Seveljević-Jaran D, Cuzić S, Dominis-Kramarić M, et al. Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglycemic rats. Skin Pharmacol Physiol. 2006;19(5):266–274.

   PMID 16785777 ↗

6. Tkalcević VI, Cuzić S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007;570(1–3):212–221.

   PMID 17628536 ↗

7. Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768–777.

   PMID 17713731 ↗

8. Skorjanec S, Dolovski Z, Kocman I, et al. Therapy for unhealed gastrocutaneous fistulas in rats. Dig Dis Sci. 2009;54(1):46–56.

   PMID 18649140 ↗

9. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155–1161.

   PMID 20225319 ↗

10. Ilic S, Drmic D, Zarkovic K, et al. High hepatotoxic dose of paracetamol produces generalized convulsions and brain damage in rats: a counteraction with the stable gastric pentadecapeptide BPC 157. J Physiol Pharmacol. 2010;61(2):241–250.

    PMID 20436226 ↗

11. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780.

    PMID 21030672 ↗

12. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126–1135.

    PMID 23755725 ↗

13. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121–1125.

    PMID 23782145 ↗

14. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077.

    PMID 25415472 ↗

15. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333.

    PMID 27847966 ↗

16. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1972–1989.

    PMID 29998800 ↗

17. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159.

    PMID 30915550 ↗

18. Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection. Curr Pharm Des. 2020;26(25):2971–2981.

    PMID 32445447 ↗

19. Sikiric P, Drmic D, Sever M, et al. Fistulas healing: stable gastric pentadecapeptide BPC 157 therapy. Curr Pharm Des. 2020;26(25):2991–3000.

    PMID 32329684 ↗

20. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13.

    PMID 34324435 ↗

21. Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533.

    PMID 34267654 ↗

22. Sikiric P, Skrtic A, Gojkovic S, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022;28(1):23–46.

    PMID 35125818 ↗

23. Vukojevic J, Milavić M, Perović D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482–487.

    PMID 34380875 ↗

24. Staresinic M, Japjec M, Vranes H, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. Biomedicines. 2022;10(12):3221.

    PMID 36551977 ↗

25. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–17.

    PMID 39325560 ↗

26. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185.

    PMID 40005999 ↗

27. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495.

    PMID 40756949 ↗

28. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619.

    PMID 40789979 ↗

29. Sikiric P, Seiwerth S, Skrtic A, et al. BPC 157 therapy: targeting angiogenesis and nitric oxide’s cytotoxic and damaging actions. Comment on Józwiak et al. Pharmaceuticals (Basel). 2025;18(10):1450.

    PMID 41155565 ↗

30. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Reply to Sikiric et al. Pharmaceuticals (Basel). 2025;18(10):1451.

    PMID 41155566 ↗

31. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223–229.

    PMID 41476424 ↗

32. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625.

    PMID 42198317 ↗

33. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921–1935.

    PMID 41966639 ↗

34. Yıldırım AK, Demirtaş H, Özer A, Arslan M. Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Sci Rep. 2026;16(1):24375.

    PMID 42204242 ↗

35. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822–837.

    PMID 42542926 ↗

36. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. 2026; online ahead of print.

    PMID 42578445 ↗

37. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current as of 22 April 2026. Regulatory document; no PMID.

    Source ↗

38. US Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. Regulatory document; no PMID.

    Source ↗